CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.13B, above the global median of $1.15B
- PositionOperating margin is 49.8%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.13BUSDvs all stocks (USD)
Trailing P/E
48.88xvs Biotechnology peers
Revenue (TTM)
450.91MUSDvs all stocks (USD)
Profit Margin
30.74%vs Biotechnology peers
Beta
0.5350xvs all stocks
52-Week Change
200.13%vs all stocks
Market Capitalization
6.13BUSDvs all stocks (USD)
Enterprise Value
6.02BUSDvs all stocks (USD)
Trailing P/E
48.88xvs Biotechnology peers
Forward P/E
12.11xvs Biotechnology peers
PEG Ratio
-0.1801xvs Biotechnology peers
Price to Sales (TTM)
13.58xvs Biotechnology peers
Price to Book (MRQ)
31.25xvs Biotechnology peers
Enterprise to Revenue
13.36xvs Biotechnology peers
Enterprise to EBITDA
35.48xvs Biotechnology peers
Gross Margin
93.27%vs Biotechnology peers
Profit Margin
30.74%vs Biotechnology peers
Operating Margin
49.81%vs Biotechnology peers
Return on Assets (TTM)
27.04%vs Biotechnology peers
Return on Equity (TTM)
131.82%vs Biotechnology peers
Revenue (TTM)
450.91MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.15USDUpdated Sep 28, 2026Quarterly Revenue Growth
1842.70%vs Biotechnology peers
Gross Profit (TTM)
417.28MUSDvs all stocks (USD)
EBITDA (TTM)
177.83MUSDvs all stocks (USD)
Net Income (TTM)
138.61MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1842.73%vs Biotechnology peers
Operating Cash Flow (TTM)
167.71MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
74.30MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
158.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.24MUSDFY2025 · Dec 31, 2025Gross Profit
145.08MUSDFY2025 · Dec 31, 2025Operating Income
-51.38MUSDvs all stocks (USD)
Pre-tax Income
-68.92MUSDFY2025 · Dec 31, 2025Net Income
-68.92MUSDFY2025 · Dec 31, 2025EBIT
-44.75MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-43.22MUSDFY2025 · Dec 31, 2025Research & Development
39.28MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
157.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
24.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-68.92MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-91.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-95.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
194.18MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-68.92MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.47MUSDFY2025 · Dec 31, 2025Other Non-cash Items
26.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.59MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.34MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-4.34MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
74.97MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-21.15MUSDFY2025 · Dec 31, 2025Other Financing Charges
1.08MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
54.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
89.10MSharesUpdated Sep 28, 2026Float Shares
63.51MSharesUpdated Sep 28, 2026Shares Short
12.38MSharesUpdated Sep 28, 2026Short Ratio
10.81daysvs all stocks
Short % of Shares Outstanding
17.16%vs all stocks
% Held by Insiders
11.32%vs all stocks
% Held by Institutions
81.83%vs all stocks
Total Cash (MRQ)
284.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.17USDUpdated Sep 28, 2026Total Debt (MRQ)
182.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9374xvs Biotechnology peers
Current Ratio (MRQ)
2.31xvs Biotechnology peers
Book Value per Share (MRQ)
2.19USDUpdated Sep 28, 2026Total Assets
327.93MUSDvs all stocks (USD)
Total Current Assets
273.40MUSDFY2025 · Dec 31, 2025Total Liabilities
283.19MUSDFY2025 · Dec 31, 2025Total Non-current Assets
54.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
147.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
135.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
190.68MUSDFY2025 · Dec 31, 2025Accounts Receivable
54.09MUSDFY2025 · Dec 31, 2025Inventory
23.80MUSDFY2025 · Dec 31, 2025Accounts Payable
3.68MUSDFY2025 · Dec 31, 2025Short-term Debt
58.89MUSDFY2025 · Dec 31, 2025Long-term Debt
139.03MUSDFY2025 · Dec 31, 2025Common Stock (Book)
87.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-626.31MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
44.75MUSDvs all stocks (USD)
52-Week Low
21.35USDUpdated Sep 28, 202652-Week High
93.61USDUpdated Sep 28, 202652-Week Change
200.13%vs all stocks
Beta
0.5350xvs all stocks
50-Day MA
75.63USDUpdated Sep 28, 2026200-Day MA
53.88USDUpdated Sep 28, 2026Avg 10-Day Volume
1.36MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.26MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
1.40USDUpdated Sep 28, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49.8%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.50Industry median: -0.24Industry P95: 0.38Peers compared: 184
Return on equity is 131.8%, higher than 95% of its Biotechnology peers (median -22.2%)Significant
Return on equity: 1.32Industry median: -0.22Industry P95: 0.23Peers compared: 184
Return on assets is 27%, higher than 95% of its Biotechnology peers (median -19%)Significant
Return on assets: 0.27Industry median: -0.19Industry P95: 0.19Peers compared: 184
Price-to-book is 31.25×, higher than 95% of its Biotechnology peers (median 4.48×)Significant
Price-to-book: 31.25Industry median: 4.48Industry P95: 30.02Peers compared: 184
Financial Health
Altman Z-Score 10.84: safe zoneNotable
Altman Z-Score: 10.84
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.13B, above the global median of $1.15BNotable
Market cap (USD): 6,125,093,411Global Median: 1,150,342,212.262
Levered free cash flow is $74.3M, above the global median of $18.98MNotable
Levered free cash flow (USD): 74,296,128Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Dajin Heavy Industry Co., Ltd.
2 interpretationsSharp Decline With Volume And Volatility ExpansionUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Chongqing Sansheng Industrial Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Fengyuan Chemical Co. Ltd.
2 interpretationsSharp Decline With Volume And Volatility ExpansionUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated